This combination in metastatic breast cancer is limited by some mutations in ESR1 which encodes ERα, such as the ESR1 Y537S or D538G mutation, which can activate estrogen signaling in the absence of estrogen and may promote PI3K pathway activation in breast cancer [95]. This evidence concerns the gene PIK3CB and breast carcinoma.